This is consistent with studies showing that inhibition of the phosphorylation levels of S6 is closely associated with inhibition of tumor growth in vivo and that sustained activation of mTORC1, as measured by P-S6 levels, was shown to contribute greatly to resistance to targeted therapies (49). This evidence concerns the gene RPS6 and neoplasm.